Next Article in Journal
A High Diet Quality Based on Dietary Recommendations Is Not Associated with Lower Incidence of Type 2 Diabetes in the Malmö Diet and Cancer Cohort
Next Article in Special Issue
Echinacoside Inhibits Glutamate Release by Suppressing Voltage-Dependent Ca2+ Entry and Protein Kinase C in Rat Cerebrocortical Nerve Terminals
Previous Article in Journal
Spatial Partitioning of miRNAs Is Related to Sequence Similarity in Overall Transcriptome
Previous Article in Special Issue
Mechanism of Mitochondrial Connexin43′s Protection of the Neurovascular Unit under Acute Cerebral Ischemia-Reperfusion Injury
Open AccessReview

Neuroprotective and Therapeutic Strategies against Parkinson’s Disease: Recent Perspectives

Division of Neurotoxicology, National Center for Toxicological Research/FDA, Bldg. 53D, HFT-32, Jefferson, AR 72079, USA
Author to whom correspondence should be addressed.
Academic Editor: Katalin Prokai-Tatrai
Int. J. Mol. Sci. 2016, 17(6), 904;
Received: 25 April 2016 / Revised: 27 May 2016 / Accepted: 30 May 2016 / Published: 8 June 2016
(This article belongs to the Special Issue Neuroprotective Strategies 2016)
Parkinsonism is a progressive motor disease that affects 1.5 million Americans and is the second most common neurodegenerative disease after Alzheimer’s. Typical neuropathological features of Parkinson’s disease (PD) include degeneration of dopaminergic neurons located in the pars compacta of the substantia nigra that project to the striatum (nigro-striatal pathway) and depositions of cytoplasmic fibrillary inclusions (Lewy bodies) which contain ubiquitin and α-synuclein. The cardinal motor signs of PD are tremors, rigidity, slow movement (bradykinesia), poor balance, and difficulty in walking (Parkinsonian gait). In addition to motor symptoms, non-motor symptoms that include autonomic and psychiatric as well as cognitive impairments are pressing issues that need to be addressed. Several different mechanisms play an important role in generation of Lewy bodies; endoplasmic reticulum (ER) stress induced unfolded proteins, neuroinflammation and eventual loss of dopaminergic neurons in the substantia nigra of mid brain in PD. Moreover, these diverse processes that result in PD make modeling of the disease and evaluation of therapeutics against this devastating disease difficult. Here, we will discuss diverse mechanisms that are involved in PD, neuroprotective and therapeutic strategies currently in clinical trial or in preclinical stages, and impart views about strategies that are promising to mitigate PD pathology. View Full-Text
Keywords: Parkinson’s disease; dopamine; l-DOPA; striatum; substantia nigra; deep brain stimulation; olfaction Parkinson’s disease; dopamine; l-DOPA; striatum; substantia nigra; deep brain stimulation; olfaction
Show Figures

Graphical abstract

MDPI and ACS Style

Sarkar, S.; Raymick, J.; Imam, S. Neuroprotective and Therapeutic Strategies against Parkinson’s Disease: Recent Perspectives. Int. J. Mol. Sci. 2016, 17, 904.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map

Back to TopTop